Clinicopathological Features of Malignant Lymphoma in Japan: The Miyagi Study
Clinicopathological Features of Malignant Lymphoma in Japan: The Miyagi Study
复制标题
DOI：
10.1620/tjem.224.151
复制
发表时间：
2011-06-01
影响因子：
2.2
通讯作者：
Harigae, Hideo
中科院分区：
文献类型：
--
作者：
Miura, Yukiko;Fukuhara, Noriko;Harigae, Hideo
宫城研究是一项恶性淋巴瘤的流行病学研究，包括免疫学和遗传分析，由覆盖日本宫城县的基于人群的登记系统构建。 2002年至2008年间宫城县共有1,552例新诊断病例纳入本研究； 75% 是 B 细胞淋巴瘤，19% 是 T 细胞和自然杀伤细胞 (T/NK 细胞) 淋巴瘤，5% 是霍奇金淋巴瘤。 B细胞淋巴瘤最常见的亚型是弥漫性大B细胞淋巴瘤，其次是滤泡性淋巴瘤和粘膜相关淋巴组织的结外边缘区淋巴瘤（分别为51%、24%和8%）。因此，滤泡性淋巴瘤占宫城县新诊断病例的18.2%；出乎意料的是，其频率与西方国家报道的相似。 T/NK 细胞淋巴瘤的常见亚型是外周 T 细胞淋巴瘤、血管免疫母细胞性 1 细胞淋巴瘤和成人 T 细胞白血病/淋巴瘤（分别为 30%、15% 和 14%）。除滤泡性淋巴瘤外，大多数数据与亚洲国家报告的数据相似。我们还通过流式细胞术分析细胞膜表达和免疫组织化学分析细胞质表达，分析了 B 细胞淋巴瘤中的 CD20 表达。 CD20蛋白的细胞膜表达可能决定B细胞淋巴瘤对抗CD20抗体治疗的敏感性。两种方法均证实 585 例初诊病例中 4 例（0.7%）和 67 例复发病例中 5 例（7.5%）缺乏 CD20 表达。此外，23例（6.5%）显示两种方法之间CD20表达存在差异。宫城研究揭示了日本恶性淋巴瘤的最新流行病学特征。
The Miyagi Study is an epidemiological study of malignant lymphoma, including immunological and genetic analyses, constructed by a population-based registration system covering Miyagi prefecture, Japan. A total of 1,552 newly diagnosed cases in Miyagi between 2002 and 2008 were enrolled in this study; 75% were B-cell lymphomas, 19% were T-cell and natural killer-cell (T/NK-cell) lymphomas, and 5% were Hodgkin's lymphomas. The most frequent subtype of B-cell lymphoma is diffuse large B-cell lymphoma, followed by follicular lymphoma and extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (51%, 24% and 8%, respectively). Thus, follicular lymphoma accounts for 18.2% of newly diagnosed cases in Miyagi; unexpectedly, its frequency is similar to that reported in Western countries. The common subtypes of T/NK-cell lymphoma are peripheral T-cell lymphoma, angioimmunoblastic 1-cell lymphoma, and adult T-cell leukemia/lymphoma (30%, 15% and 14%, respectively). Most of the data are similar to those reported in Asian countries, except for follicular lymphoma. We also analyzed the CD20 expression in B-cell lymphomas by flow cytometry for the cell membrane expression and by immunohistochemistry for the cytoplasmic expression. The cell membrane expression of CD20 protein may determine the susceptibility of B-cell lymphomas to anti-CD20 antibody therapy. The lack of CD20 expression was confirmed by both methods in 4 cases of 585 newly diagnosed cases (0.7%) and in 5 of 67 recurrent cases (7.5%). Furthermore, 23 cases (6.5%) showed the discrepancy of CD20 expression between both methods. The Miyagi Study has revealed the latest epidemiological features of malignant lymphoma in Japan.